Xspray Pharma Future Growth

Future criteria checks 2/6

Xspray Pharma is forecast to grow revenue at 86.7% per annum.

Key information

n/a

Earnings growth rate

n/a

EPS growth rate

Biotechs earnings growth38.9%
Revenue growth rate86.7%
Future return on equityn/a
Analyst coverage

Low

Last updated16 Feb 2024

Recent future growth updates

Recent updates

We Think Xspray Pharma (STO:XSPRAY) Needs To Drive Business Growth Carefully

Feb 25
We Think Xspray Pharma (STO:XSPRAY) Needs To Drive Business Growth Carefully

We're Not Very Worried About Xspray Pharma's (STO:XSPRAY) Cash Burn Rate

May 11
We're Not Very Worried About Xspray Pharma's (STO:XSPRAY) Cash Burn Rate

We Think Xspray Pharma (STO:XSPRAY) Can Afford To Drive Business Growth

Feb 01
We Think Xspray Pharma (STO:XSPRAY) Can Afford To Drive Business Growth

We're Not Very Worried About Xspray Pharma's (STO:XSPRAY) Cash Burn Rate

Oct 26
We're Not Very Worried About Xspray Pharma's (STO:XSPRAY) Cash Burn Rate

We're Not Very Worried About Xspray Pharma's (STO:XSPRAY) Cash Burn Rate

Jun 20
We're Not Very Worried About Xspray Pharma's (STO:XSPRAY) Cash Burn Rate

We're Hopeful That Xspray Pharma (STO:XSPRAY) Will Use Its Cash Wisely

Mar 19
We're Hopeful That Xspray Pharma (STO:XSPRAY) Will Use Its Cash Wisely

Do Institutions Own Xspray Pharma AB (publ) (STO:XSPRAY) Shares?

Feb 12
Do Institutions Own Xspray Pharma AB (publ) (STO:XSPRAY) Shares?

Here's Why We're Watching Xspray Pharma's (STO:XSPRAY) Cash Burn Situation

Dec 04
Here's Why We're Watching Xspray Pharma's (STO:XSPRAY) Cash Burn Situation

Earnings and Revenue Growth Forecasts

OM:XSPRAY - Analysts future estimates and past financials data (SEK Millions)
DateRevenueEarningsFree Cash FlowCash from OpAvg. No. Analysts
12/31/20261,605N/AN/AN/A1
12/31/2025789N/A901841
12/31/2024131596-382-2971
12/31/2023N/A-180-256-203N/A
9/30/2023N/A-180-268-206N/A
6/30/2023N/A-170-242-160N/A
3/31/2023N/A-148-223-128N/A
12/31/2022N/A-132-238-110N/A
9/30/2022N/A-128-216-85N/A
6/30/2022N/A-114-198-79N/A
3/31/2022N/A-102-185-67N/A
12/31/2021N/A-97-148-52N/A
9/30/2021N/A-60-146-53N/A
6/30/2021N/A-57-145-49N/A
3/31/2021N/A-56-141-46N/A
12/31/2020N/A-52-141-48N/A
9/30/2020N/A-56-141-48N/A
6/30/2020N/A-55-140-44N/A
3/31/2020N/A-49-135-35N/A
12/31/2019N/A-46-126-34N/A
9/30/2019-22-41-115-29N/A
6/30/2019-14-34-97-24N/A
3/31/2019-6-30-91-27N/A
12/31/20180-23-65-18N/A
9/30/201831-17-62-25N/A
6/30/201828-16-45-12N/A
3/31/201829-8-38-7N/A
12/31/20170-14-36-12N/A
9/30/2017351N/A12N/A
6/30/201730-3N/A-2N/A
3/31/201721-7N/A-6N/A
12/31/201621-4N/A-2N/A
12/31/20155-12N/A-13N/A

Analyst Future Growth Forecasts

Earnings vs Savings Rate: Insufficient data to determine if XSPRAY's forecast earnings growth is above the savings rate (1%).

Earnings vs Market: Insufficient data to determine if XSPRAY's earnings are forecast to grow faster than the Swedish market

High Growth Earnings: Insufficient data to determine if XSPRAY's earnings are expected to grow significantly over the next 3 years.

Revenue vs Market: XSPRAY's revenue (86.7% per year) is forecast to grow faster than the Swedish market (1.7% per year).

High Growth Revenue: XSPRAY's revenue (86.7% per year) is forecast to grow faster than 20% per year.


Earnings per Share Growth Forecasts


Future Return on Equity

Future ROE: Insufficient data to determine if XSPRAY's Return on Equity is forecast to be high in 3 years time


Discover growth companies

Simply Wall Street Pty Ltd (ACN 600 056 611), is a Corporate Authorised Representative (Authorised Representative Number: 467183) of Sanlam Private Wealth Pty Ltd (AFSL No. 337927). Any advice contained in this website is general advice only and has been prepared without considering your objectives, financial situation or needs. You should not rely on any advice and/or information contained in this website and before making any investment decision we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice. Please read our Financial Services Guide before deciding whether to obtain financial services from us.